Novo-Backed Drug Developer MapLight Therapeutics Files for IPO - Bloomberg
Skip to content
Bloomberg the Company & Its ProductsThe Company & its ProductsBloomberg Terminal Demo RequestBloomberg Anywhere Remote LoginBloomberg Anywhere LoginBloomberg Customer SupportCustomer Support
BloombergConnecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
For CustomersBloomberg Anywhere Remote LoginSoftware UpdatesManage Products and Account Information
SupportAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000
CompanyAboutCareersInclusion at BloombergTech at BloombergPhilanthropySustainabilityBloomberg Beta
CommunicationsPress AnnouncementsPress Contacts
FollowFacebookInstagramLinkedInYouTube
ProductsBloomberg TerminalDataTradingRiskComplianceIndices
Industry ProductsBloomberg LawBloomberg TaxBloomberg GovernmentBloombergNEF
MediaBloomberg MarketsBloomberg TechnologyBloomberg PursuitsBloomberg PoliticsBloomberg OpinionBloomberg BusinessweekBloomberg Live ConferencesBloomberg RadioBloomberg TelevisionNews Bureaus
Media ServicesBloomberg Media DistributionAdvertising
CompanyAboutCareersInclusion at BloombergTech at BloombergPhilanthropySustainabilityBloomberg Beta
CommunicationsPress AnnouncementsPress Contacts
FollowFacebookInstagramLinkedInYouTube
ProductsBloomberg TerminalDataTradingRiskComplianceIndices
Industry ProductsBloomberg LawBloomberg TaxBloomberg GovernmentBloombergNEF
MediaBloomberg MarketsBloomberg TechnologyBloomberg PursuitsBloomberg PoliticsBloomberg OpinionBloomberg BusinessweekBloomberg Live ConferencesBloomberg RadioBloomberg TelevisionNews Bureaus
Media ServicesBloomberg Media DistributionAdvertising
BloombergConnecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
For CustomersBloomberg Anywhere Remote LoginSoftware UpdatesManage Contracts and Orders
SupportAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000
Sign InSubscribeSearchLive TVMarketsChevron DownEconomicsIndustriesTechPoliticsBusinessweekOpinionMoreChevron DownUS EditionChevron DownMenuSubscribeUS Stocks:Today’s Markets WrapImproved ExpectationsMag 7 BubbleFaster Spot ETF ListingsQuarterly EarningsStock Movers PodcastBackForwardMarketsNovo-Backed Drug Developer MapLight Therapeutics Files for IPOFacebookXLinkedInEmailLinkGiftFacebookXLinkedInEmailLinkGiftGift this articleContact us:Provide news feedback or report an errorConfidential tip?Send a tip to our reportersSite feedback:Take our SurveyNew WindowFacebookXLinkedInEmailLinkGiftBy Anthony HughesSeptember 19, 2025 at 9:45 PM UTCBookmarkSaveMapLight Therapeutics Inc. filed for an initial public offering, becoming one of few biotechnology firms to move forward with a listing in a tough year for the sector.The Redwood City, California-based clinical-stage biopharmaceutical firm’s lead product candidate consists of two drugs for schizophrenia and Alzheimer’s disease psychosis (ADP) delivered in a fixed-dose combination, according to MapLight’s filing Friday with the US Securities and Exchange Commission.HomeBTV+Market DataOpinionAudioOriginalsMagazineEventsNewsMarketsEconomicsTechnologyPoliticsGreenCryptoAIWork & LifeWealthPursuitsBusinessweekCityLabSportsEqualityManagement & WorkMarket DataStocksCommoditiesRates & BondsCurrenciesFuturesSectorsEconomic CalendarExploreNewslettersExplainersPointed News QuizThe Big TakeGraphicsSubmit a TipAbout UsTerms of ServiceDo Not Sell or Share My Personal InformationTrademarksPrivacy PolicyCareersMade in NYCAdvertiseAd ChoicesHelp©2025 Bloomberg L.P. All Rights Reserved.